The DOI matches its Crossref record; 134 of the 136 references it cites were found in a registry or an index.
Tumor-Associated Macrophages: From Mechanisms to Therapy
Open accessAbstract
The tumor microenvironment is a complex ecology of cells that evolves with and provides support to tumor cells during the transition to malignancy. Among the innate and adaptive immune cells recruited to the tumor site, macrophages are particularly abundant and are present at all stages of tumor progression. Clinical studies and experimental mouse models indicate that these macrophages generally play a protumoral role. In the primary tumor, macrophages can stimulate angiogenesis and enhance tumor cell invasion, motility, and intravasation. During monocytes and/or metastasis, macrophages prime the premetastatic site and promote tumor cell extravasation, survival, and persistent growth. Macrophages are also immunosuppressive, preventing tumor cell attack by natural killer and T cells during tumor progression and after recovery from chemo- or immunotherapy. Therapeutic success in targeting these protumoral roles in preclinical models and in early clinical trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, TAM-based therapeutic strategies are being developed that aim at TAM targeting, TAM re-education, and TAM depletion [88, 96, 101, 102].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [88]
The cited source says what the claim attributes to it.
In the citing paper
“Many therapy strategies have attempted to alter the polarization of macrophages’ “re-programming” or prevent monocyte tumor infiltration (Noy and Pollard, 2014).”
From Sysrev: A FAIR Platform for Data Curation and Systematic Evidence Review (2021) · cites this paper as Noy and Pollard, 2014
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [167]
In the citing paper
“The production of colony stimulating factor 1 (CSF-1; also known as macrophage colony stimulating factor) by BCCs, has been reported to stimulate the recruitment of macrophages to primary breast tumors, leading to the secretion by tumor-associated macrophages (TAMs) of epidermal growth factor, which binds to its cognate receptor on BCCs to stimulate invasion and metastasis [36–38].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Forget, M. A., Voorhees, J. L., Cole, S. L., Dakhlallah, D. A., Patterson, I. L., Gross, A. C., Moldovan, L., Mo, X. M., Evans, R., Marsh, C. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098623 · Cited by 79 · cited 2×
“Interestingly, CSF1 upregulates TIE2 on TAMs (Forget et al., 2014) indicating a link between CSF1, TIE2 macrophages, and the induction of the angiogenic switch.”
BackgroundRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…the ways in which the microenvironmental support to tumors is the acquisition of a vasculature that provides oxygenation, as well as the nutrition and waste disposal required for growth above a certain size in a process often referred to as the ‘‘angiogenic switch’’ (Hanahan and Weinberg, 2011).”
BackgroundCoussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111 · cited 1×
“Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”
BackgroundImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · cited 4×
“Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”
BackgroundInfluentialMicroenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 3×
“…SPARC) that increases tumor cell-ECM interaction and thus migration (Sangaletti et al., 2008), Cathepsin proteases that remodel the matrix and release sequestered growth factors (Laoui et al., 2011; Quail and Joyce, 2013) and TGF-b that promotes EMT of the invading tumor cells (Bonde et al., 2012).”
BackgroundMolecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 1×
“TheseM-MDSCs have greater immunosuppressive potency than the granulocytic ones and are further defined as F4/80+ a marker also found on inflammatory monocytes (Gabrilovich and Nagaraj, 2009; Gabrilovich et al., 2012).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 2×
“References to these polarizing agents can be found in (De Palma and Lewis, 2013; Sica and Mantovani, 2012). above strongly support targeting the destruction or redifferentiation of macrophages as an important part of combinatorial therapies in human cancer patients.”
BackgroundAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189 · cited 1×
“…the activated macrophages responding to IFN-g, TNF-a, and Toll-like receptor 4 (TLR4) activation capable of killing pathogens through mechanisms such as iNOS, and (2) alternatively activated macrophages responding to IL-4 and IL-13 involved in antiparasitic immunity and in asthma (Gordon, 2003).”
BackgroundMacrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,349 · cited 11×
“Furthermore, in most large-scale transcriptome analysis, macrophages have a mixed phenotype expressing both M1 and M2 markers (Qian and Pollard, 2010).”
BackgroundInfluentialSelf-citation
Cited by
Sorted by citations
Items 801–900 of 1,010
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
The Impact of the Adipose Organ Plasticity on Inflammation and Cancer Progression
Corrêa, L. H., Cardoso, G. S. H. R., & Magalhães, K. G. (2019) · Cells · doi:10.3390/cells8070662 · Cited by 98
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Eguren‐Santamaría, I., Sanmamed, M. F., Goldberg, S. B., Kluger, H. M., Idoate, M. A., Lu, B. Y., Corral, J., Schalper, K. A., Herbst, R. S., & Bazo, I. G. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0798 · Cited by 90
Fatty Acid Metabolism in Ovarian Cancer: Therapeutic Implications
Yoon, H., & Lee, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042170 · Cited by 92
An Immune Dysregulation in MPN
Barosi, G. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0227-0 · Cited by 91
NLRC4 suppresses melanoma tumor progression independently of inflammasome activation
Janowski, A. M., Colegio, O. R., Hornick, E. E., McNiff, J. M., Martin, M. D., Badovinac, V. P., Norian, L. A., Zhang, W., Cassel, S. L., & Sutterwala, F. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86953 · Cited by 94
Zhao, S.-J., Jiang, Y.-Q., Xu, N.-W., Li, Q., Zhang, Q., Wang, S.-Y., Li, J., Wang, Y.-H., Zhang, Y., Jiang, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.403 · Cited by 89
Ye, J., Yang, Y., Dong, W., Gao, Y., Meng, Y., Wang, H., Li, L., Jin, J., Ji, M., Xia, X., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s207589 · Cited by 87
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Wang, S., Xie, K., & Liu, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690112 · Cited by 90
Opzoomer, J. W., Anstee, J. E., Dean, I., Hill, E. J., Bouybayoune, I., Caron, J., Muliaditan, T., Gordon, P., Sosnowska, D., Nuamah, R. A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg9518 · Cited by 94
Zeng, W., Xiong, L., Wu, W., Li, S., Liu, J., Yang, L., Lao, L., Huang, P., Zhang, M., Chen, H., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02540-2 · Cited by 88
Antagonizing Integrin β3 Increases Immunosuppression in Cancer
Su, X., Esser, A. K., Amend, S. R., Xiang, J., Xu, Y., Ross, M. H., Fox, G. C., Kobayashi, T., Steri, V., Roomp, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2663 · Cited by 87
Huffaker, T. B., Lee, S.-H., Tang, W. W., Wallace, J. A., Alexander, M., Runtsch, M. C., Larsen, D. K., Thompson, J., Ramstead, A. G., Voth, W. P., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.808121 · Cited by 89
Irey, E. A., Lassiter, C. M., Brady, N. J., Chuntova, P., Wang, Y., Knutson, T. P., Henzler, C. M., Chaffee, T. S., Vogel, R. I., Nelson, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816410116 · Cited by 84
Generation of Myeloid Cells in Cancer: The Spleen Matters
Wu, C., Hua, Q., & Zheng, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01126 · Cited by 89
Moreira, D., Sampath, S., Won, H., White, S. V., Su, Y., Alcantara, M. B., Wang, C., Lee, P. P., Maghami, E. G., Massarelli, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137001 · Cited by 87
Roles of Neutrophils in Glioma and Brain Metastases
Lin, Y.-J., Wei, K., Chen, P., Lim, M. K., & Hwang, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701383 · Cited by 88
Reactive Oxygen Species: Do They Play a Role in Adaptive Immunity?
Bassoy, E. Y., Walch, M., & Martinvalet, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.755856 · Cited by 93
The Many Roles of Macrophages in Skeletal Muscle Injury and Repair
Wang, X., & Zhou, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.952249 · Cited by 101
Xiao, L., Zhang, L., Guo, C., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2024) · 癌症：英文版 · doi:10.1002/cac2.12579 · Cited by 87
“M1 macrophages are classically activated macrophages with the ability to kill tumor cells and inhibit tumor angiogenesis and lym-phangiogenesis, while M2 macrophages are believed to contribute to the immunosuppressive TME [265].”
BackgroundIlangumaran, S., Villalobos-Hernandez, A., Bobbala, D., & Ramanathan, S. (2016) · Cytokine · doi:10.1016/j.cyto.2015.12.013 · Cited by 82
Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment
García-Gómez, A., Rodríguez‐Ubreva, J., & Ballestar, E. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.02.013 · Cited by 88
Biology and therapeutic targeting of tumour‐associated macrophages
Beltraminelli, T., & Palma, M. D. (2020) · The Journal of Pathology · doi:10.1002/path.5403 · Cited by 87
Multi-scale modeling of macrophage—T cell interactions within the tumor microenvironment
Cess, C. G., & Finley, S. D. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008519 · Cited by 84
Chen, M., Miao, Y., Qian, K., Zhou, X. H., Guo, L., Qiu, Y., Wang, R., Gan, Y., & Zhang, X. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01210 · Cited by 86
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 89
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Comen, E. A., Bowman, R. L., & Kleppe, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00056 · Cited by 87
Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis
Al-Qadami, G. H., Sebille, Y. Z. A. V., Le, H. V., & Bowen, J. M. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1595586 · Cited by 87
Nola, R. D., Menga, A., Castegna, A., Loizzi, V., Ranieri, G., Cicinelli, E., & Cormio, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102401 · Cited by 87
Danieau, G., Morice, S., Rédiní, F., Verrecchia, F., & Royer, B. B.-L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153751 · Cited by 88
Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages
Alaluf, E., Vokaer, B., Detavernier, A., Azouz, A., Splittgerber, M., Carrette, A., Boon, L., Libert, F., Soares, M. P., Moine, A. L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133929 · Cited by 86
Zheng, Y., Wang, Z., Wei, S., Liu, Z., & Chen, G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.034 · Cited by 84
Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer
Shi, J., Song, X., Traub, B., Luxenhofer, M., & Kornmann, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062998 · Cited by 85
Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4
Santiso, A., Heinemann, Á., & Kargl, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000901 · Cited by 92
Polyphenols as Immunomodulatory Compounds in the Tumor Microenvironment: Friends or Foes?
Focaccetti, C., Izzi, V., Benvenuto, M., Fazi, S., Ciuffa, S., Giganti, M. G., Potenza, V., Manzari, V., Modesti, A., & Bei, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071714 · Cited by 86
Li, Z., Feng, C., Guo, J., Hu, X., & Xie, D. (2019) · Functional & Integrative Genomics · doi:10.1007/s10142-019-00696-x · Cited by 83
Fujita, M., Yamaguchi, R., Hasegawa, T., Shimada, S., Arihiro, K., Hayashi, S., Maejima, K., Nakano, K., Fujimoto, A., Ono, A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102659 · Cited by 84
Lopez‐Bergami, P., & Barbero, G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09878-7 · Cited by 84
Potential Application of Exosomes in Vaccine Development and Delivery
Huda, M. N., & Nurunnabi, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-021-03143-4 · Cited by 87
Single-cell RNA sequencing reveals distinct immunology profiles in human keloid
Feng, C., Shan, M., Xia, Y., Zheng, Z., He, K., Wei, Y., Song, K., Meng, T., Liu, H., Hao, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940645 · Cited by 88
Glycolytic pathway affects differentiation of human monocytes to regulatory macrophages
Suzuki, H., Hisamatsu, T., Chiba, S., Mori, K., Kitazume, M. T., Shimamura, K., Nakamoto, N., Matsuoka, K., Ebinuma, H., Naganuma, M., et al. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.05.009 · Cited by 81
Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
Luo, Z.-W., Liu, P.-P., Wang, Z.-X., Chen, C.-Y., & Xie, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586580 · Cited by 89
The immunomodulatory potential of natural compounds in tumor-bearing mice and humans
Pan, P., Huang, Y., Oshima, K., Yearsley, M., Zhang, J., ARNOLD, M. W., Yu, J., & Wang, L.-S. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1537237 · Cited by 83
Amino acid metabolism as drug target in autoimmune diseases
Mondanelli, G., Iacono, A., Carvalho, A., Orabona, C., Volpi, C., Pallotta, M. T., Matino, D., Esposito, S., & Grohmann, U. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.02.004 · Cited by 84
Deshmukh, S. K., Srivastava, S. K., Poosarla, T., Dyess, D. L., Holliday, N. P., Singh, A. P., & Singh, S. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.68 · Cited by 85
Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
Grégoire, H., Roncali, L., Rousseau, A., Chérel, M., Delneste, Y., Jeannin, P., Hindré, F., & Garcion, E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00368 · Cited by 88
Macrophages in tumor: An inflammatory perspective
Goswami, K. K., Bose, A., & Baral, R. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108875 · Cited by 88
Leukemia inhibitory factor, a double-edged sword with therapeutic implications in human diseases
Wang, J., Chang, C., Yang, X. F., Zhou, F., Liu, J., Feng, Z., & Hu, W. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.12.016 · Cited by 84
Translational Horizons in the Tumor Microenvironment: Harnessing Breakthroughs and Targeting Cures
Sun, Y. (2015) · Medicinal Research Reviews · doi:10.1002/med.21338 · Cited by 85
Li, Y., Zheng, Y., Li, T., Wang, Q., Qian, J., Lu, Y., Zhang, M., Bi, E., Yang, M., Reu, F. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4523 · Cited by 83
Nanoparticles Targeting STATs in Cancer Therapy
Ashrafizadeh, M., Ahmadi, Z., Kotla, N. G., Afshar, E. G., Samarghandian, S., Mandegary, A., Pardakhty, A., Mohammadinejad, R., & Sethi, G. (2019) · Cells · doi:10.3390/cells8101158 · Cited by 83
Zhuang, H., Dai, X., Zhang, X., Mao, Z., & Huang, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109636 · Cited by 83
Song, X., Wan, Z., Chen, T., Fu, Y. S., Jiang, K., Yi, X., Ke, H., Dong, J., Yang, L., Li, L., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.001 · Cited by 82
FOXOs in cancer immunity: Knowns and unknowns
Deng, Y., Wang, F., Hughes, T. L., & Yu, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.005 · Cited by 84
Integrated cancer tissue engineering models for precision medicine
Bregenzer, M. E., Horst, E. N., Mehta, P., Novak, C. M., Raghavan, S. A., Snyder, C. S., & Mehta, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216564 · Cited by 84
Stacchiotti, S., Ferrari, S., Redondo, A., Hindi, N., Palmerini, E., Salgado, M. Á. V., Frezza, A. M., Casali, P. G., Gutierrez, A. M., Pousa, A. L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30319-5 · Cited by 82
Zhang, T., Lip, H., He, C., Cai, P., Wang, Z., Henderson, J. T., Rauth, A. M., & Wu, X. Y. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900543 · Cited by 83
Sakamoto, Y., Mima, K., Ishimoto, T., Ogata, Y., Imai, K., Miyamoto, Y., Akiyama, T., Daitoku, N., Hiyoshi, Y., Iwatsuki, M., et al. (2021) · Cancer Science · doi:10.1111/cas.15126 · Cited by 85
Zhu, C., Kros, J. M., van der Weiden, M., Zheng, P., Cheng, C., & Mustafa, D. A. M. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0405-5 · Cited by 81
Lehmann, B., Biburger, M., Brückner, C., Ipsen-Escobedo, A., Gordan, S., Lehmann, C. H. K., Voehringer, D., Winkler, T., Schaft, N., Dudziak, D., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aah6413 · Cited by 87
Chemoresistance in Cancer Cells: Exosomes As Potential Regulators of Therapeutic Tumor Heterogeneity
Sharma, A. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0184 · Cited by 80
Chloroquine and nanoparticle drug delivery: A promising combination
Pelt, J., Busatto, S., Mauro Ferrari, B., Thompson, E. A., Mody, K., & Wolfram, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.007 · Cited by 84
Targeted Delivery of Zoledronate to Tumor-Associated Macrophages for Cancer Immunotherapy
Zang, X., Zhang, X., Hu, H., Qiao, M., Zhao, X., Deng, Y., & Chen, D. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00261 · Cited by 81
Nauclér, C. S., Geisler, J., & Vetvik, K. K. (2019) · Oncotarget · doi:10.18632/oncotarget.27016 · Cited by 81
Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site
Nasrollahzadeh, E., Razi, S., Keshavarz‐Fathi, M., Mazzone, M., & Rezaei, N. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02616-6 · Cited by 83
Recent Advances of Gold Compounds in Anticancer Immunity
Yue, S., Luo, M., Liu, H., & Wei, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00543 · Cited by 86
Jin, X., Zhang, N., Yan, T., Wei, J., Hao, L., Sun, C., Zhao, H., & Jiang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573039 · Cited by 91
“Moreover, TAMs suppress T cell activity by recruiting regulatory T cells via chemokines, inducing Foxp3+ iTreg cells through IL-10 and TGF-b , and depleting L-arginine via arginase I, which impairs TCR signaling (18).”
Schürch, C. M., Roelli, M. A., Forster, S., Wasmer, M.-H., Bruehl, F. K., Maire, R., Pancrazio, S. D., Ruepp, M., Giger, R., Perren, A. A., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0555 · Cited by 81
Papin, A., Tessoulin, B., Bellanger, C., Moreau, A., Bris, Y. L., Maisonneuve, H., Moreau, P., Touzeau, C., Amiot, M., Pellat‐Deceunynck, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0463-3 · Cited by 83
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Song, C., Luo, Y., Luo, C.-B., Xin, H.-Y., Yang, X.-R., Shi, Y.-H., Wang, Z., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.07.014 · Cited by 67
Linkage of CD8+ T cell exhaustion with high-fat diet-induced tumourigenesis
Kado, T., Nawaz, A., Takikawa, A., Usui, I., & Tobe, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-48678-0 · Cited by 80
Wu, X., Qu, D., Weygant, N., Peng, J., & Houchen, C. W. (2020) · Cancers · doi:10.3390/cancers12020274 · Cited by 80
Tumor Associated Macrophages and TAMs‐Based Anti‐Tumor Nanomedicines
Cheng, Y., Song, S., Wu, P., Lyu, B., Qin, M., Sun, Y., Sun, A., Mu, L.-M., Xu, F., Zhang, L., et al. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100590 · Cited by 80
An, Y., Ji, C., Zhang, H., Jiang, Q., Maitz, M. F., Pan, J., Luo, R., & Wang, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c16280 · Cited by 82
Reversing the polarization of tumor-associated macrophages inhibits tumor metastasis
Yuan, R., Li, S., Geng, H., Wang, X., Guan, Q., Li, X., Ren, C., & Yuan, X. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.05.014 · Cited by 82
Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells
Plebanek, M. P., Bhaumik, D., Bryce, P. J., & Thaxton, C. S. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0981 · Cited by 79
The Emerging Role of the Microenvironment in Endometrial Cancer
Sahoo, S. S., Zhang, X. D., Hondermarck, H., & Tanwar, P. S. (2018) · Cancers · doi:10.3390/cancers10110408 · Cited by 83
Anti‐angiogenic effects of CD73‐specific siRNA‐loaded nanoparticles in breast cancer‐bearing mice
Ghalamfarsa, G., Rastegari, A., Atyabi, F., Hassannia, H., Hojjat‐Farsangi, M., Ghanbari, A., Anvari, E., Mohammadi, J., Azizi, G., Masjedi, A., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26743 · Cited by 81
Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells
Yong, S., Chung, J. Y., Song, Y., Kim, J., Ra, S., & Kim, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119401 · Cited by 81
Maimon, A., Levi-Yahid, V., Ben‐Meir, K., Halpern, A., Talmi, Z., Priya, S., Mizraji, G., Mistriel-Zerbib, S., Berger, M., Baniyash, M., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci126089 · Cited by 84
Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy
Cai, T., Liu, H., Zhang, S., Hu, J. Y., & Zhang, L. L. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01146-2 · Cited by 79
Pernot, S., Évrard, S., & Khatib, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850856 · Cited by 84
Immune Tumor Microenvironment in Ovarian Cancer Ascites
Almeida-Nunes, D. L., Mendes‐Frias, A., Silvestre, R., Dinis‐Oliveira, R. J., & Ricardo, S. A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810692 · Cited by 89
Reprogramming of macrophages — new opportunities for therapeutic targeting
Schultze, J. L. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.007 · Cited by 79
Gan, L., Qiu, Z., Huang, J., Li, Y., Huang, H., Xiang, T., Wan, J., Hui, T., Lin, Y. S., Li, H., et al. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15943 · Cited by 79
The biology of serous cavity macrophages
Bain, C. C., & Jenkins, S. J. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.003 · Cited by 78
Silva, V. L., & Al-Jamal, W. T. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.013 · Cited by 77
The interactions and communications in tumor resistance to radiotherapy: Therapy perspectives
Ashrafizadeh, M., Farhood, B., Musa, A. E., Taeb, S., & Najafi, M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106807 · Cited by 79
The LEAP Program: Lenvatinib Plus Pembrolizumab for the Treatment of Advanced Solid Tumors
Taylor, M. H., Schmidt, E. V., Dutcus, C. E., Pinheiro, E. M., Funahashi, Y., Lubiniecki, G. M., & Rasco, D. W. (2020) · Future Oncology · doi:10.2217/fon-2020-0937 · Cited by 80
Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?
Deligne, C., & Midwood, K. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620773 · Cited by 84
Nanomedicine-based strategies to target and modulate the tumor microenvironment
Mendes, B. B., Sousa, D. P., Conniot, J., & Conde, J. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.001 · Cited by 80
CD169 identifies an anti‐tumour macrophage subpopulation in human hepatocellular carcinoma
Zhang, Y., Li, J., Jiang, Z.-Z., Li, L., Wu, Y., & Zheng, L. (2016) · The Journal of Pathology · doi:10.1002/path.4720 · Cited by 78
Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma
Gutiérrez‐González, A., Martínez‐Moreno, M., Samaniego, R., Arellano‐Sánchez, N., Salinas-Muñoz, L., Relloso, M., Valeri, A., Martínez‐López, J., Corbí, A. L., Hidalgo, A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-695395 · Cited by 78
Lu, C., Yeh, D., Lai, C.-Y., Liu, Y., Huang, L., Lee, A. Y., Jin, S.-L. C., & Chuang, T. (2018) · Oncogene · doi:10.1038/s41388-018-0411-0 · Cited by 78
Hippo Pathway in Mammalian Adaptive Immune System
Yamauchi, T., & Moroishi, T. (2019) · Cells · doi:10.3390/cells8050398 · Cited by 82
Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells
Tanne, A., Muniz, L. R., Puzio-Kuter, A., Leonova, K. I., Gudkov, A. V., Ting, D. T., Monasson, R., Cocco, S., Levine, A. J., Bhardwaj, N., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517584112 · Cited by 74
Innate and acquired immune surveillance in the postdissemination phase of metastasis
Velozo, H. G., Robles, I., & Werb, Z. (2017) · FEBS Journal · doi:10.1111/febs.14325 · Cited by 78
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 78
Advances in the analysis of single extracellular vesicles: A critical review
Hilton, S. H., & White, I. M. (2021) · Sensors and Actuators Reports · doi:10.1016/j.snr.2021.100052 · Cited by 74
Xu, T., Yu, S., Zhang, J., & Wu, S. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01198-9 · Cited by 79
Metadata
- Authors
- Noy, R., & Pollard, J. W.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Pollard, Jeffrey W.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 41
- Issue
- 1
- Pages
- 49-61
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC4137410
- OpenAlex
- W1971620413
- Cited by
- 4,089
- References
- 136
- Citations by year
- 2026: 258 · 2025: 326 · 2024: 359 · 2023: 393 · 2022: 485 · 2021: 479 · 2020: 424 · 2019: 379 · 2018: 297 · 2017: 285 · 2016: 215 · 2015: 157 · 2014: 27
- FWCI
- 22.25
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-11-20)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust (101067, 101067/Z/13/Z)
- National Institutes of Health (UL1TR001073)
- National Cancer Institute (P01CA100324, R01CA172451)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor-associated macrophages, tumor microenvironment, tumor angiogenesis, tumor invasion, metastasis, pre-metastatic niche, immunosuppression, natural killer cells, T cells, macrophage-targeted therapy, combination cancer therapy
- MeSH terms
- Animals, Cell Movement, Cell Survival, Cell Transformation, Neoplastic, Humans, Immunosuppression Therapy, Macrophages, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Cell Lineage, Cell Proliferation, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
